UroGen Pharma Ltd (NASDAQ:URGN) price on Friday, March 21, rose 0.92% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $12.13.
A look at the stock’s price movement, the close in the last trading session was $12.02, moving within a range at $11.8 and $12.2. The beta value (5-Year monthly) was 1.125. Turning to its 52-week performance, $20.70 and $9.03 were the 52-week high and 52-week low respectively. Overall, URGN moved 13.26% over the past month.
UroGen Pharma Ltd’s market cap currently stands at around $559.12 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-09.
Analysts have a consensus estimate of 22.69M for the company’s revenue for the quarter, with a low and high estimate of 20.14M and 29.53M respectively. The average forecast suggests up to a 20.82% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 123.32M, representing a 36.42% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that URGN is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend URGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
URGN’s current price about 16.23% and 15.05% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 71.64, while 7-day volatility ratio is 4.59% and 6.13% in the 30-day chart. Further, UroGen Pharma Ltd (URGN) has a beta value of 0.78, and an average true range (ATR) of 0.59. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $25 and high of $25. Looking at the price targets, the low is -106.1% off current price level while to achieve the yearly target high, price needs to move -106.1%. Nonetheless, investors will most likely welcome a -106.1% jump to $25 which is the analysts’ median price.
If we refocus on UroGen Pharma Ltd (NASDAQ:URGN), historical trading data shows that trading volumes averaged 0.4 over the past 10 days and 379.43K over the past 3 months. The company’s latest data on shares outstanding shows there are 42.23 million shares.
The 17.09% of UroGen Pharma Ltd’s shares are in the hands of company insiders while institutional holders own 80.23% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.12 million on 2025-02-28, giving us a short ratio of 17.74. The data shows that as of 2025-02-28 short interest in UroGen Pharma Ltd (URGN) stood at 1484.0001 of shares outstanding, with shares short falling to 6.16 million registered in 2025-01-31. Current price change has pushed the stock 13.90% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the URGN stock continues to rise going into the next quarter.
